Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Biomol Struct Dyn ; 42(3): 1381-1391, 2024.
Article in English | MEDLINE | ID: mdl-37071766

ABSTRACT

Four new hybrid compounds (H1-H4) bearing pyrazole (S1 and S2) and chalcone (P1 and P2) fragments were synthesized and characterized. Compounds were assayed for their ability to inhibit the proliferation of human lung (A549) and colon (Caco-2) cancer cell lines. Besides, toxicity against normal cells was determined using the human umbilical vein endothelial cells (HUVEC). In silico molecular docking, molecular dynamics (MD) simulation and absorption, distribution, metabolism, excretion, and toxicity (ADMET) studies were carried out to predict the binding modes, protein stability, drug-likeness and toxicity of the reported compounds. The in vitro anticancer activity of the tested compounds revealed dose-dependent cell-specific cytotoxicity. In silico studies revealed that the compounds have a good binding affinity, possess appropriate drug-likeness properties and have low toxicity profiles.Communicated by Ramaswamy H. Sarma.


Subject(s)
Antineoplastic Agents , Chalcone , Chalcones , Humans , Molecular Dynamics Simulation , Molecular Docking Simulation , Molecular Structure , Structure-Activity Relationship , Chalcones/pharmacology , Cell Line, Tumor , Chalcone/pharmacology , Caco-2 Cells , Endothelial Cells , Antineoplastic Agents/chemistry , Drug Design , Cell Proliferation , Pyrazoles/pharmacology , Pyrazoles/chemistry
2.
Bioinformation ; 17(7): 673-679, 2021.
Article in English | MEDLINE | ID: mdl-35283582

ABSTRACT

Mono-therapeutics is rarely effective as a treatment option, which limits the survival of patients in advanced grade aggressive cancers. Combinational therapeutics (multiple drugs for multiple targets) to combat cancer is gaining momentum in recent years. Hence, it is of interest to document known data for combinational therapeutics in cancer treatment. An amalgamation of therapeutic agents enhances the efficacy and potency of the therapy. Combinational therapy can potentially target multiple pathways that are necessary for the cancer cells to proliferate, and/or target molecules, which may help cancer to become more aggressive and metastasize. In this review, we discuss combinational therapeutics, which include human γδ T cells in combinations with biologically active anti-cancer molecules, which synergistically may produce promising combinational therapeutics.

SELECTION OF CITATIONS
SEARCH DETAIL
...